Viviane Caceres
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Viviane Caceres has a total of 134 co-authors. Here are the top co-authors by number of shared publications:
- Nazareno Paolocci
Johns Hopkins Medical Institutions
7 shared publications - Brian O'ROurke
Johns Hopkins University School of Medicine
3 shared publications - Carlo Gabriele Tocchetti
Department of Translational Medical Sciences, Federico II University, 80131 Naples, Italy
3 shared publications - Miguel Antonio Aon
Translational Gerontology Branch, National Institute on Aging, National Institutes of Health, Baltimore, Maryland, USA;
3 shared publications Regina C. Spadari-Bratfisch
Department of Biosciences, Federal University of São Paulo (UNIFESP), Santos, São Paulo 04021-001, Brazil
3 shared publicationsSa Shi
Division of Cardiology, Department of Medicine, Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, United States
3 shared publications
Latest Publications
- 1 August 2025
- Published by Human Kinetics in Pediatric Exercise Science
- Vol. 37 (3) , 286-294
Light-Intensity Physical Activity and Sedentary Behavior Are Associated With Blood Pressure Levels in Adolescents
Purpose: To investigate the associations between physical activity (PA) intensities, sedentary behavior (SB), and blood pressure (BP) in adolescents, according to sex. Method: This cross-sectional study involved 95 male and female adolescents aged 15–18 years. Accelerometry was used to measure time spent in light-intensity PA (LPA), moderate to vigorous PA (MVPA), and vigorous PA, and SB. The BP was determined using an automated sphygmomanometer. Statistical analyses included multiple linear regression and command margins. Results: Significant associations were found between systolic BP (SBP) and time spent in LPA (B = −0.08; 95% CI, −0.15 to −0.01) and SB (B = 0.071; 95% CI, 0.004–0.138), albeit only in boys. Furthermore, an interaction was observed between time spent in SB and MVPA for SBP in boys (B = −0.002; 95% CI, −0.004 to −0.0008). The main interaction effect of increasing SBP was a combination of Conclusions: Increased time in LPA and reduced time spent in SB during the day are associated with lower SBP in male adolescents. Additionally, the relation between SB and SBP was attenuated by MVPA. These findings provide crucial insights for PA recommendations to promote cardiovascular health in adolescents.
- 1 August 2025
- Published by Human Kinetics in Pediatric Exercise Science
- Vol. 37 (3) , 286-294
Light-Intensity Physical Activity and Sedentary Behavior Are Associated With Blood Pressure Levels in Adolescents
Purpose: To investigate the associations between physical activity (PA) intensities, sedentary behavior (SB), and blood pressure (BP) in adolescents, according to sex. Method: This cross-sectional study involved 95 male and female adolescents aged 15–18 years. Accelerometry was used to measure time spent in light-intensity PA (LPA), moderate to vigorous PA (MVPA), and vigorous PA, and SB. The BP was determined using an automated sphygmomanometer. Statistical analyses included multiple linear regression and command margins. Results: Significant associations were found between systolic BP (SBP) and time spent in LPA (B = −0.08; 95% CI, −0.15 to −0.01) and SB (B = 0.071; 95% CI, 0.004–0.138), albeit only in boys. Furthermore, an interaction was observed between time spent in SB and MVPA for SBP in boys (B = −0.002; 95% CI, −0.004 to −0.0008). The main interaction effect of increasing SBP was a combination of Conclusions: Increased time in LPA and reduced time spent in SB during the day are associated with lower SBP in male adolescents. Additionally, the relation between SB and SBP was attenuated by MVPA. These findings provide crucial insights for PA recommendations to promote cardiovascular health in adolescents.
- Open Access
- 24 January 2025
- Published by Wiley in Pharmacology Research & Perspectives
- Vol. 13 (1) , e70039
A Clinical Practice‐Based Comparison of Conventional and Individualized Dosing Strategies for Therapeutic Enoxaparin
To understand differences in anti‐factor‐Xa levels produced by two different dosing strategies (conventional and individualized) for therapeutic enoxaparin in a cohort of hospital inpatients. A multicenter, retrospective cohort study over a two‐ and a half‐year period for inpatients with stable renal function and on therapeutic enoxaparin. Anti‐factor‐Xa levels were taken 3–5 h after enoxaparin administration and a minimum of 48 h of dosing. The final analysis included 278 patients from five hospitals: conventional dosing was used for 141, while 137 were given an unconventional dose, that is, individualized for their renal function and weight. Out‐of‐range levels were frequent (35% to 40% of all inpatients). After adjustment for age, renal function, and body mass index (BMI), the conventional group was more likely to experience above‐range levels (> 1.0 IU/mL; OR 2.50 [95% CI 1.38–4.56], p < 0.003) than the individualized group. Individualized dosing was independently associated with higher odds of a below‐range anti‐Xa level (< 0.5 IU/mL) compared to conventional dosing (OR 2.27 [95% CI 1.07–4.76], p = 0.03). Within the conventional group, above‐range levels were significantly and independently associated with decreasing renal function (OR 0.97, 95% CI 0.96–0.99, p = 0.004) and with increasing BMI (OR 1.06, 95% CI 1.01–1.10, p = 0.02). No such associations were seen with an individualized approach. Clinical event rates were low and not different between groups (p > 0.24). Conventional therapeutic dosing of enoxaparin exposed people with obesity or renal impairment to more frequent above‐range anti‐factor‐Xa levels; individualizing the dose could improve this but might expose people to subtherapeutic levels. More research is needed.
- 24 January 2025
- Published by Wiley in Pharmacology Research & Perspectives
- Vol. 13 (1) , e70039
Open AccessA Clinical Practice‐Based Comparison of Conventional and Individualized Dosing Strategies for Therapeutic Enoxaparin
To understand differences in anti‐factor‐Xa levels produced by two different dosing strategies (conventional and individualized) for therapeutic enoxaparin in a cohort of hospital inpatients. A multicenter, retrospective cohort study over a two‐ and a half‐year period for inpatients with stable renal function and on therapeutic enoxaparin. Anti‐factor‐Xa levels were taken 3–5 h after enoxaparin administration and a minimum of 48 h of dosing. The final analysis included 278 patients from five hospitals: conventional dosing was used for 141, while 137 were given an unconventional dose, that is, individualized for their renal function and weight. Out‐of‐range levels were frequent (35% to 40% of all inpatients). After adjustment for age, renal function, and body mass index (BMI), the conventional group was more likely to experience above‐range levels (> 1.0 IU/mL; OR 2.50 [95% CI 1.38–4.56], p < 0.003) than the individualized group. Individualized dosing was independently associated with higher odds of a below‐range anti‐Xa level (< 0.5 IU/mL) compared to conventional dosing (OR 2.27 [95% CI 1.07–4.76], p = 0.03). Within the conventional group, above‐range levels were significantly and independently associated with decreasing renal function (OR 0.97, 95% CI 0.96–0.99, p = 0.004) and with increasing BMI (OR 1.06, 95% CI 1.01–1.10, p = 0.02). No such associations were seen with an individualized approach. Clinical event rates were low and not different between groups (p > 0.24). Conventional therapeutic dosing of enoxaparin exposed people with obesity or renal impairment to more frequent above‐range anti‐factor‐Xa levels; individualizing the dose could improve this but might expose people to subtherapeutic levels. More research is needed.
- 21 November 2024
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 91 (4) , 1182-1190
Determination of the optimal obesity‐adjusted dosing weight for enoxaparin
Aims: The ideal dosing weight metric for enoxaparin remains elusive. Dosing remains focused on actual body weight, which may inadvertently increase the risk of bleeding in those with obesity, or ideal weight, which may underdose those with obesity. Our aim was to determine the optimal obesity‐adjusted enoxaparin dosing weight.Methods: Multisite retrospective data were collected over a 2.0‐year period for those with minimum 48 h of in‐hospital twice‐daily enoxaparin and factor anti‐Xa level 3–5 h postdose (n = 220). Multiple linear regression calculated the associated variance between a range of nominal dosing weights and factor anti‐Xa levels, adjusted for renal function. Dosing weights were calculated as ideal body weight (IBW) and then adjusted for increasing percentages of weight above IBW, i.e. IBW + 10% above IBW, IBW + 20% etc. up to actual body weight. A similar approach was used for lean body weight (LBW).Results: For body mass index ≥30 kg/m2 optimal variance explained by dosing weight metrics was at IBW + 40% (23%) and similarly for LBW + 40% (23%). Using actual body weight (ABW) had lowest associated variance with factor anti‐Xa levels (18%) followed by unadjusted IBW (13%) or unadjusted LBW (19%). In those with body mass index 2 there was similar associated variance in the ranges of IBW + 20–50% and LBW 10–40% (21%).Conclusion: Compared to IBW + 40% or LBW + 40% use of ABW to calculate dose was poorly associated with factor anti‐Xa levels, as was IBW or LBW. IBW + 40% and LBW + 40% require further study as a dosing weight metric and may provide a more consistent factor anti‐Xa response in those with obesity.
- 21 November 2024
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 91 (4) , 1182-1190
Determination of the optimal obesity‐adjusted dosing weight for enoxaparin
Aims: The ideal dosing weight metric for enoxaparin remains elusive. Dosing remains focused on actual body weight, which may inadvertently increase the risk of bleeding in those with obesity, or ideal weight, which may underdose those with obesity. Our aim was to determine the optimal obesity‐adjusted enoxaparin dosing weight.Methods: Multisite retrospective data were collected over a 2.0‐year period for those with minimum 48 h of in‐hospital twice‐daily enoxaparin and factor anti‐Xa level 3–5 h postdose (n = 220). Multiple linear regression calculated the associated variance between a range of nominal dosing weights and factor anti‐Xa levels, adjusted for renal function. Dosing weights were calculated as ideal body weight (IBW) and then adjusted for increasing percentages of weight above IBW, i.e. IBW + 10% above IBW, IBW + 20% etc. up to actual body weight. A similar approach was used for lean body weight (LBW).Results: For body mass index ≥30 kg/m2 optimal variance explained by dosing weight metrics was at IBW + 40% (23%) and similarly for LBW + 40% (23%). Using actual body weight (ABW) had lowest associated variance with factor anti‐Xa levels (18%) followed by unadjusted IBW (13%) or unadjusted LBW (19%). In those with body mass index 2 there was similar associated variance in the ranges of IBW + 20–50% and LBW 10–40% (21%).Conclusion: Compared to IBW + 40% or LBW + 40% use of ABW to calculate dose was poorly associated with factor anti‐Xa levels, as was IBW or LBW. IBW + 40% and LBW + 40% require further study as a dosing weight metric and may provide a more consistent factor anti‐Xa response in those with obesity.
- 30 December 2018
- Published by Wiley in The Journal of Physiology
- Vol. 598 (7) , 1393-1415
Metabolic remodelling of glucose, fatty acid and redox pathways in the heart of type 2 diabetic mice
Key points: Hearts from type 2 diabetic animals display perturbations in excitation–contraction coupling, impairing myocyte contractility and delaying relaxation, along with altered substrate consumption patterns. Under high glucose and β‐adrenergic stimulation conditions, palmitate can, at least in part, offset left ventricle (LV) dysfunction in hearts from diabetic mice, improving contractility and relaxation while restoring coronary perfusion pressure. Fluxome calculations of central catabolism in diabetic hearts show that, in the presence of palmitate, there is a metabolic remodelling involving tricarboxylic acid cycle, polyol and pentose phosphate pathways, leading to improved redox balance in cytoplasmic and mitochondrial compartments. Under high glucose and increased energy demand, the metabolic/fluxomic redirection leading to restored redox balance imparted by palmitate helps explain maintained LV function and may contribute to designing novel therapeutic approaches to prevent cardiac dysfunction in diabetic patients. Type‐2 diabetes (T2DM) leads to reduced myocardial performance, and eventually heart failure. Excessive accumulation of lipids and glucose is central to T2DM cardiomyopathy. Previous data showed that palmitate (Palm) or glutathione preserved heart mitochondrial energy/redox balance under excess glucose, rescuing β‐adrenergic‐stimulated cardiac excitation–contraction coupling. However, the mechanisms underlying the accompanying improved contractile performance have been largely ignored. Herein we explore in intact heart under substrate excess the metabolic remodelling associated with cardiac function in diabetic db/db mice subjected to stress given by β‐adrenergic stimulation with isoproterenol and high glucose compared to their non‐diabetic controls (+/+, WT) under euglycaemic conditions. When perfused with Palm, T2DM hearts exhibited improved contractility/relaxation compared to WT, accompanied by extensive metabolic remodelling as demonstrated by metabolomics–fluxomics combined with bioinformatics and computational modelling. The T2DM heart metabolome showed significant differences in the abundance of metabolites in pathways related to glucose, lipids and redox metabolism. Using a validated computational model of heart's central catabolism, comprising glucose and fatty acid (FA) oxidation in cytoplasmic and mitochondrial compartments, we estimated that fluxes through glucose degradation pathways are ∼2‐fold lower in heart from T2DM vs. WT under all conditions studied. Palm addition elicits improvement of the redox status via enhanced β‐oxidation and decreased glucose uptake, leading to flux‐redirection away from redox‐consuming pathways (e.g. polyol) while maintaining the flux through redox‐generating pathways together with glucose–FA ‘shared fuelling’ of oxidative phosphorylation. Thus, available FAs such as Palm may help improve function via enhanced redox balance in T2DM hearts during peaks of hyperglycaemia and increased workload.
- 30 December 2018
- Published by Wiley in The Journal of Physiology
- Vol. 598 (7) , 1393-1415
Metabolic remodelling of glucose, fatty acid and redox pathways in the heart of type 2 diabetic mice
Key points: Hearts from type 2 diabetic animals display perturbations in excitation–contraction coupling, impairing myocyte contractility and delaying relaxation, along with altered substrate consumption patterns. Under high glucose and β‐adrenergic stimulation conditions, palmitate can, at least in part, offset left ventricle (LV) dysfunction in hearts from diabetic mice, improving contractility and relaxation while restoring coronary perfusion pressure. Fluxome calculations of central catabolism in diabetic hearts show that, in the presence of palmitate, there is a metabolic remodelling involving tricarboxylic acid cycle, polyol and pentose phosphate pathways, leading to improved redox balance in cytoplasmic and mitochondrial compartments. Under high glucose and increased energy demand, the metabolic/fluxomic redirection leading to restored redox balance imparted by palmitate helps explain maintained LV function and may contribute to designing novel therapeutic approaches to prevent cardiac dysfunction in diabetic patients. Type‐2 diabetes (T2DM) leads to reduced myocardial performance, and eventually heart failure. Excessive accumulation of lipids and glucose is central to T2DM cardiomyopathy. Previous data showed that palmitate (Palm) or glutathione preserved heart mitochondrial energy/redox balance under excess glucose, rescuing β‐adrenergic‐stimulated cardiac excitation–contraction coupling. However, the mechanisms underlying the accompanying improved contractile performance have been largely ignored. Herein we explore in intact heart under substrate excess the metabolic remodelling associated with cardiac function in diabetic db/db mice subjected to stress given by β‐adrenergic stimulation with isoproterenol and high glucose compared to their non‐diabetic controls (+/+, WT) under euglycaemic conditions. When perfused with Palm, T2DM hearts exhibited improved contractility/relaxation compared to WT, accompanied by extensive metabolic remodelling as demonstrated by metabolomics–fluxomics combined with bioinformatics and computational modelling. The T2DM heart metabolome showed significant differences in the abundance of metabolites in pathways related to glucose, lipids and redox metabolism. Using a validated computational model of heart's central catabolism, comprising glucose and fatty acid (FA) oxidation in cytoplasmic and mitochondrial compartments, we estimated that fluxes through glucose degradation pathways are ∼2‐fold lower in heart from T2DM vs. WT under all conditions studied. Palm addition elicits improvement of the redox status via enhanced β‐oxidation and decreased glucose uptake, leading to flux‐redirection away from redox‐consuming pathways (e.g. polyol) while maintaining the flux through redox‐generating pathways together with glucose–FA ‘shared fuelling’ of oxidative phosphorylation. Thus, available FAs such as Palm may help improve function via enhanced redox balance in T2DM hearts during peaks of hyperglycaemia and increased workload.
- Open Access
- 7 June 2018
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 13 (6) , e0198769
Physical activity moderates the deleterious relationship between cardiovascular disease, or its risk factors, and quality of life: Findings from two population-based cohort studies in Southern Brazil and South Australia
Few studies have investigated the relationship between physical activity (PA) of low intensity and duration with quality of life (QoL) among individuals at risk or with cardiovascular disease (CVD). To investigate whether PA of different intensity and duration moderates the relationship between CVD and its risk factors (obesity, hypertension, diabetes, dyslipidaemia) and QoL in adults. Population-based cross-sectional studies using data from the EpiFloripa Cohort Study (Southern Brazil; n = 1,220, 38.8±12.0 years, 48.2% males) and the North West Adelaide Health Study (NWAHS, South Australia; n = 1,661, 43.7±11.1 years, 49.7% males). The physical and psychological domains of QoL were assessed using the WHOQOL-Bref (EpiFloripa) or the SF-36 (NWAHS) questionnaires. The diagnosis of CVD and its risk factors were self-reported. PA was self-reported and quantified by its intensity [“walking” or moderate/vigorous (MVPA)] and duration (none, 1–150, ≥150 min/week). Both studies were analysed separately, and results were adjusted for sociodemographic variables. Participants at risk or with CVD from both studies showed a lower QoL than ‘healthy’ individuals with a stronger relationship for the physical domain. PA duration showed a direct-trend relationship with QoL, but the associations were stronger for MVPA in both studies. However, when stratified by health status, the magnitude of the association between “walking” duration and a higher physical QoL was greater among those at risk or with CVD compared to ‘healthy’ individuals. Conversely, among Australians with CVD, MVPA was associated with a better physical QoL only when its duration was ≥150 min/week. All associations were stronger in the NWAHS than in the Brazilian study. “Walking” was more prevalent than MVPA and was consistently associated with a better physical QoL among those at risk or with CVD. These findings should be considered in the design of public health interventions designed to increase PA and improve QoL.
- 7 June 2018
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 13 (6) , e0198769
Open AccessPhysical activity moderates the deleterious relationship between cardiovascular disease, or its risk factors, and quality of life: Findings from two population-based cohort studies in Southern Brazil and South Australia
Few studies have investigated the relationship between physical activity (PA) of low intensity and duration with quality of life (QoL) among individuals at risk or with cardiovascular disease (CVD). To investigate whether PA of different intensity and duration moderates the relationship between CVD and its risk factors (obesity, hypertension, diabetes, dyslipidaemia) and QoL in adults. Population-based cross-sectional studies using data from the EpiFloripa Cohort Study (Southern Brazil; n = 1,220, 38.8±12.0 years, 48.2% males) and the North West Adelaide Health Study (NWAHS, South Australia; n = 1,661, 43.7±11.1 years, 49.7% males). The physical and psychological domains of QoL were assessed using the WHOQOL-Bref (EpiFloripa) or the SF-36 (NWAHS) questionnaires. The diagnosis of CVD and its risk factors were self-reported. PA was self-reported and quantified by its intensity [“walking” or moderate/vigorous (MVPA)] and duration (none, 1–150, ≥150 min/week). Both studies were analysed separately, and results were adjusted for sociodemographic variables. Participants at risk or with CVD from both studies showed a lower QoL than ‘healthy’ individuals with a stronger relationship for the physical domain. PA duration showed a direct-trend relationship with QoL, but the associations were stronger for MVPA in both studies. However, when stratified by health status, the magnitude of the association between “walking” duration and a higher physical QoL was greater among those at risk or with CVD compared to ‘healthy’ individuals. Conversely, among Australians with CVD, MVPA was associated with a better physical QoL only when its duration was ≥150 min/week. All associations were stronger in the NWAHS than in the Brazilian study. “Walking” was more prevalent than MVPA and was consistently associated with a better physical QoL among those at risk or with CVD. These findings should be considered in the design of public health interventions designed to increase PA and improve QoL.
- Open Access
- 24 June 2015
- Published by American Diabetes Association in Diabetes
- Vol. 64 (10) , 3573-3587
Removal of Abnormal Myofilament O-GlcNAcylation Restores Ca2+ Sensitivity in Diabetic Cardiac Muscle
Contractile dysfunction and increased deposition of O-linked β-N-acetyl-d-glucosamine (O-GlcNAc) in cardiac proteins are a hallmark of the diabetic heart. However, whether and how this posttranslational alteration contributes to lower cardiac function remains unclear. Using a refined β-elimination/Michael addition with tandem mass tags (TMT)–labeling proteomic technique, we show that CpOGA, a bacterial analog of O-GlcNAcase (OGA) that cleaves O-GlcNAc in vivo, removes site-specific O-GlcNAcylation from myofilaments, restoring Ca2+ sensitivity in streptozotocin (STZ) diabetic cardiac muscles. We report that in control rat hearts, O-GlcNAc and O-GlcNAc transferase (OGT) are mainly localized at the Z-line, whereas OGA is at the A-band. Conversely, in diabetic hearts O-GlcNAc levels are increased and OGT and OGA delocalized. Consistent changes were found in human diabetic hearts. STZ diabetic hearts display increased physical interactions of OGA with α-actin, tropomyosin, and myosin light chain 1, along with reduced OGT and increased OGA activities. Our study is the first to reveal that specific removal of O-GlcNAcylation restores myofilament response to Ca2+ in diabetic hearts and that altered O-GlcNAcylation is due to the subcellular redistribution of OGT and OGA rather than to changes in their overall activities. Thus, preventing sarcomeric OGT and OGA displacement represents a new possible strategy for treating diabetic cardiomyopathy.
- 24 June 2015
- Published by American Diabetes Association in Diabetes
- Vol. 64 (10) , 3573-3587
Open AccessRemoval of Abnormal Myofilament O-GlcNAcylation Restores Ca2+ Sensitivity in Diabetic Cardiac Muscle
Contractile dysfunction and increased deposition of O-linked β-N-acetyl-d-glucosamine (O-GlcNAc) in cardiac proteins are a hallmark of the diabetic heart. However, whether and how this posttranslational alteration contributes to lower cardiac function remains unclear. Using a refined β-elimination/Michael addition with tandem mass tags (TMT)–labeling proteomic technique, we show that CpOGA, a bacterial analog of O-GlcNAcase (OGA) that cleaves O-GlcNAc in vivo, removes site-specific O-GlcNAcylation from myofilaments, restoring Ca2+ sensitivity in streptozotocin (STZ) diabetic cardiac muscles. We report that in control rat hearts, O-GlcNAc and O-GlcNAc transferase (OGT) are mainly localized at the Z-line, whereas OGA is at the A-band. Conversely, in diabetic hearts O-GlcNAc levels are increased and OGT and OGA delocalized. Consistent changes were found in human diabetic hearts. STZ diabetic hearts display increased physical interactions of OGA with α-actin, tropomyosin, and myosin light chain 1, along with reduced OGT and increased OGA activities. Our study is the first to reveal that specific removal of O-GlcNAcylation restores myofilament response to Ca2+ in diabetic hearts and that altered O-GlcNAcylation is due to the subcellular redistribution of OGT and OGA rather than to changes in their overall activities. Thus, preventing sarcomeric OGT and OGA displacement represents a new possible strategy for treating diabetic cardiomyopathy.
- 1 January 2015
- Published by Elsevier in Biophysical Journal
- Vol. 108 (2) , 315a
Palmitate Re-Directs Glucose Utilization in Type 2 Diabetic Hearts, Improving Function: A Metabolomic-Fluxomic Study
- 1 January 2015
- Published by Elsevier in Biophysical Journal
- Vol. 108 (2) , 315a
Palmitate Re-Directs Glucose Utilization in Type 2 Diabetic Hearts, Improving Function: A Metabolomic-Fluxomic Study
- 1 January 2015
- Published by Elsevier in Biophysical Journal
- Vol. 108 (1) , 163-172
From Metabolomics to Fluxomics: A Computational Procedure to Translate Metabolite Profiles into Metabolic Fluxes
- 1 January 2015
- Published by Elsevier in Biophysical Journal
- Vol. 108 (1) , 163-172
From Metabolomics to Fluxomics: A Computational Procedure to Translate Metabolite Profiles into Metabolic Fluxes
- Open Access
- 28 August 2014
- Published by Wiley in Physiological Reports
- Vol. 2 (8) , e12115
Early postnatal rat ventricle resection leads to long-term preserved cardiac function despite tissue hypoperfusion
One‐day‐old mice display a brief capacity for heart regeneration after apex resection. We sought to examine this response in a different model and to determine the impact of this early process on long‐term tissue perfusion and overall cardiac function in response to stress. Apical resection of postnatal rats at day 1 (P1) and 7 (P7) rendered 18 ± 1.0% and 16 ± 1.3% loss of cardiac area estimated by magnetic resonance imaging (MRI), respectively ( P > 0.05). P1 was associated with evidence of cardiac neoformation as indicated by Troponin I and Connexin 43 expression at 21 days postresection, while in the P7 group mainly scar tissue replacement ensued. Interestingly, there was an apparent lack of uniform alignment of newly formed cells in P1, and we detected cardiac tissue hypoperfusion for both groups at 21 and 60 days postresection using SPECT scanning. Direct basal cardiac function at 60 days, when the early lesion is undetectable, was preserved in all groups, whereas under hemodynamic stress the degree of change on LVDEP, Stroke Volume and Stroke Work indicated diminished overall cardiac function in P7 ( P < 0.05). Furthermore, the End‐Diastolic Pressure–Volume relationship and increased interstitial collagen deposition in P7 is consistent with increased chamber stiffness. Taken together, we provide evidence that early cardiac repair response to apex resection in rats also leads to cardiomyocyte neoformation and is associated to long‐term preservation of cardiac function despite tissue hypoperfusion.
- 28 August 2014
- Published by Wiley in Physiological Reports
- Vol. 2 (8) , e12115
Open AccessEarly postnatal rat ventricle resection leads to long-term preserved cardiac function despite tissue hypoperfusion
One‐day‐old mice display a brief capacity for heart regeneration after apex resection. We sought to examine this response in a different model and to determine the impact of this early process on long‐term tissue perfusion and overall cardiac function in response to stress. Apical resection of postnatal rats at day 1 (P1) and 7 (P7) rendered 18 ± 1.0% and 16 ± 1.3% loss of cardiac area estimated by magnetic resonance imaging (MRI), respectively ( P > 0.05). P1 was associated with evidence of cardiac neoformation as indicated by Troponin I and Connexin 43 expression at 21 days postresection, while in the P7 group mainly scar tissue replacement ensued. Interestingly, there was an apparent lack of uniform alignment of newly formed cells in P1, and we detected cardiac tissue hypoperfusion for both groups at 21 and 60 days postresection using SPECT scanning. Direct basal cardiac function at 60 days, when the early lesion is undetectable, was preserved in all groups, whereas under hemodynamic stress the degree of change on LVDEP, Stroke Volume and Stroke Work indicated diminished overall cardiac function in P7 ( P < 0.05). Furthermore, the End‐Diastolic Pressure–Volume relationship and increased interstitial collagen deposition in P7 is consistent with increased chamber stiffness. Taken together, we provide evidence that early cardiac repair response to apex resection in rats also leads to cardiomyocyte neoformation and is associated to long‐term preservation of cardiac function despite tissue hypoperfusion.
- 1 January 2014
- Published by Elsevier in Nitric Oxide
- Vol. 36, 58-66
Cardioprotective mechanism of S-nitroso-N-acetylcysteine via S-nitrosated betadrenoceptor-2 in the LDLr−/− mice
- 1 January 2014
- Published by Elsevier in Nitric Oxide
- Vol. 36, 58-66
Cardioprotective mechanism of S-nitroso-N-acetylcysteine via S-nitrosated betadrenoceptor-2 in the LDLr−/− mice